Journal of pediatric gastroenterology and nutrition
Cure8 research brief
Why This Matters
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and treatment planning discussions.
Who Should Pay Attention
Pediatric patients with Crohn’s disease and their parents/caregivers; pediatric gastroenterologists and clinicians managing biologic therapy; researchers using registry data.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used registry data to find factors linked with not reaching remission within two years and with taking longer to reach different remission milestones (first remission, corticosteroid-free remission, sustained remission).
The authors report that patient characteristics (sex, age, BMI) and the timing/type of biologic/immunomodulator therapy were associated with those outcomes. The findings reflect associations in a large observational dataset rather than results from a randomized trial.
Keep In Mind
This is an abstract-based summary grounded in the PubMed abstract of a Journal of Pediatric Gastroenterology and Nutrition article (registry observational study). The analysis identifies associations; it does not prove that any treatment causes the outcomes described.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of pediatric gastroenterology and nutrition
AuthorsJonathan Van Hecke, Gigi Veereman, Koen Huysentruyt +7 more
InstitutionGeneeskunde en Farmacie, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
Refractory Crohn's Disease: Effective Therapy by Inhibition of Interleukin 12 and Interleukin 23
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...